Asset profile
SHR-3167
Peptide
Evidence outlook · results not reported
NCT06688123 · Type 2 Diabetes
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT06688123: The study used randomization and an active insulin glargine comparator in 275 participants, but it was open-label rather than blinded. Its primary endpoint was change in HbA1c, a surrogate measure, and no results are currently available to show whether the primary comparison was met.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
80 competitors in this universe: 19 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 76 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SHR-3167: this drug | Phase 2 | Peptide | Insulin receptor (basal) | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Detemir (Levemir) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Glargine (Lantus / Toujeo) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Icodec (Awiqli) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor (basal) | ||
| LY2963016 (Basaglar) | Approved | Peptide | Insulin receptor (basal) | ||
| LY900014 (Lyumjev) | Approved | Peptide | Insulin receptor (basal) | ||
| SAR341402 | Approved | Peptide | Insulin receptor (basal) | ||
| GZR33 | Phase 3 | Peptide | Insulin receptor (basal) | ||
| IcoSema (Kyinsu) | Phase 3 | Peptide | Insulin receptor (basal), GLP-1 receptor | ||
| INS068 | Phase 3 | Peptide | Insulin receptor (basal) | ||
| Insulin Efsitora Alfa | Phase 3 | Protein / enzyme therapeutic | Insulin receptor (basal) | ||
| ORMD-0801 | Phase 3 | Peptide | Insulin receptor (basal) |
…and 65 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
13 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
2027 (1)
March 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.